Network / Interactive Map / Entity profile
Servier
Research organisation
Servier
Description
As an independent international pharmaceutical company, Servier is committed to therapeutic progress for the benefit of patients.
Our ambition is to become a recognised, focused and innovative player in oncology by targeting cancers that are difficult to treat. This is why the Group devotes nearly 70% of its R&D budget to the development of targeted and innovative oncology therapies. In these fields, Servier focuses on a limited number of specific pathologies in which the precise characterisation of patients makes it possible to offer a targeted therapeutic response, thanks to precision medicine.
Our ambition is to become a recognised, focused and innovative player in oncology by targeting cancers that are difficult to treat. This is why the Group devotes nearly 70% of its R&D budget to the development of targeted and innovative oncology therapies. In these fields, Servier focuses on a limited number of specific pathologies in which the precise characterisation of patients makes it possible to offer a targeted therapeutic response, thanks to precision medicine.
Servier
Address
905 Rte de Saran
45520 Gidy, France
45520 Gidy, France
Contact
christophe.aussourd@servier.com
Description
As an independent international pharmaceutical company, Servier is committed to therapeutic progress for the benefit of patients.
Our ambition is to become a recognised, focused and innovative player in oncology by targeting cancers that are difficult to treat. This is why the Group devotes nearly 70% of its R&D budget to the development of targeted and innovative oncology therapies. In these fields, Servier focuses on a limited number of specific pathologies in which the precise characterisation of patients makes it possible to offer a targeted therapeutic response, thanks to precision medicine.
Our ambition is to become a recognised, focused and innovative player in oncology by targeting cancers that are difficult to treat. This is why the Group devotes nearly 70% of its R&D budget to the development of targeted and innovative oncology therapies. In these fields, Servier focuses on a limited number of specific pathologies in which the precise characterisation of patients makes it possible to offer a targeted therapeutic response, thanks to precision medicine.
Matchmaking
Connect with Servier
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways
Not yet on COBIOE directory?
Want to access to more data?
Want to contact this entity?